Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

BRIXADI

BUPRENORPHINE

Standard Dose
24MG/0.48ML (50MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview BRIXADI is listed in Drugs@FDA under application 210136 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BUPRENORPHINE Form and strength SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS - 24MG/0.48ML (50MG/ML) Sponsor BRAEBURN Submission history Latest submission status date: 2025-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRIXADI is listed in Drugs@FDA under application 210136 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BUPRENORPHINE Form and strength SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS - 24MG/0.48ML (50MG/ML) Sponsor BRAEBURN Submission history Latest submission status date: 2025-12-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.